Abstract:  

Breast cancer is the most common female malignant tumor and has become the most common cancer in the world.With the advent of targeted drugs and the improvement of systemic treatment for breast cancer, the prognosis of patients with early breast cancer has been greatly improved. However, for patients with refractory breast cancer after multi'line therapy and newly diagnosed distant metastasis, the antibodies or cytotoxic drugs alone cannot meet the therapeutic needs. Antibody-drug conjugates (ADCs) are immunoconjugates that connect cytotoxic drugs and monoclonal antibodies via the molecular linker, which can selectively deliver cytotoxic drugs to cancer cells through monoclonal antibodies targeting tumor antigens, and so they have the advantages of strong selectivity, high efficiency and low toxicity. In recent years, ADCs have played an increasingly important role in the treatment of breast cancer. This review summarizes the main mechanism of ADCs,the current status and progress of ADCs for breast cancer.

Key words: Breast cancer')">">, Antibody'drug conjugates">'drug conjugates')">">, Efficacy')">">, Safety